✦ LIBER ✦

A Phase I study of acivicin in refractory pediatric solid tumors

✍ Scribed by Sylvain Baruchel; Mark Bernstein; V. Michael Whitehead; Susan Devine; Beverly Bell; Ronald Dubowy; Holcombe Grier; Cynthia Kretschmar; Anne-Marie Langevin; Teresa Vietti

Publisher: Springer US
Year: 1995
Tongue: English
Weight: 444 KB
Volume: 13
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00873802

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I trial of fazarabine in refract

A phase I trial of fazarabine in refractory pediatric solid tumors

✍ Mark L. Bernstein; V. Michael Whitehead; Holcombe Grier; Ron Dubowy; Vita Land; 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 289 KB

Phase I study of fotemustine in pediatri

Phase I study of fotemustine in pediatric patients with refractory brain tumors

✍ Darren R. Hargrave; Eric Bouffet; Janet Gammon; Nauman Tariq; Ron M. Grant; Sylv 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 1 views

## Abstract ## BACKGROUND Fotemustine is a nitrosourea with theoretic and preclinical advantages over the original analogs, carmustine and lomustine, in the treatment of brain tumors. This is the first pediatric Phase I study of fotemustine. ## METHODS Patients younger than 21 with recurrent/res

Phase I trial of trimetrexate in pediatr

Phase I trial of trimetrexate in pediatric solid tumors: A pediatric oncology group study

✍ Pappo, Alberto S. ;Vats, Tribhawan ;Williams, Thomas E. ;Bernstein, Mark ;Kamen, 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 283 KB

## Abstract Trimetrexate (TMTX), a lipophilic antifol, was evaluated in a Pediatric Oncology Group (POG) Phase I trial in children with refractory solid tumors. TMTX was administered intravenously daily × 5 every three weeks. Starting dose was 6.4 mg/m^2^/day. Dose was escalated by 20% until the ma

5-fluorouracil and cis-platinum in the t

5-fluorouracil and cis-platinum in the treatment of refractory solid tumors: A pediatric oncology group phase I — II study

✍ Land, Vita J. ;Dyment, Paul G. ;Starling, Kenneth ;Strandjord, Sarah E. ;Chan, R 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB

## Abstract Eleven patients with osteogenic sarcoma (9), Hodgkin disease (1), and mesenchymal sarcoma (1), were treated with 5‐fluorouracil (5‐FU) and cisplatin (DDP). Myelosuppression and vomiting of variable degrees occurred in all. No responses were seen.

Phase 1 study of oxaliplatin and irinote

Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors : A Children's Oncology Group Study

✍ Lisa M. McGregor; Sheri L. Spunt; Wayne L. Furman; Clinton F. Stewart; Paula Sch 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 533 KB

Phase I study of mitonafide in solid tum

Phase I study of mitonafide in solid tumors

✍ Manuel Llombart; Andrés Poveda; Ernesto Forner; Carlos Fernández-Martos; Cristób 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 293 KB